SYMPK

Across TCGA pan-cancer cohorts, SYMPK Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated SYMPK data layer compared with 21 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher SYMPK Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SYMPK expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUSC show a favorable association.

KIRC, LUAD, and BRCA are the cancer types where SYMPK Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.054	0.881	<.001	42	view →
LUAD	DFS	Median	II,III,IV	0.296	0.687	.001	26	view →
BRCA	OS	Median	All	0.193	0.581	.002	14	view →
MESO	OS	Median	II,III,IV	0.261	0.564	.023	9	view →
TGCT	DFS	Median	All	0.067	0.802	.001	6	view →
LIHC	DFS	Median	III,IV	0.040	0.361	<.001	6	view →
UCEC	DFS	Median	All	0.937	0.826	.029	6	view →
DLBC	OS	Median	All	0.613	0.945	.049	3	view →
LUSC	DFS	Median	All	0.891	0.361	.013	2	view →
SKCM	OS	Median	III,IV	1.000	0.382	.031	1	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

SYMPK–KIRC (OS)

Open the KIRC breakdown →